Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canakinumab biosimilar - Mabpharm

Next Previous
Search
Drug Profile

Canakinumab biosimilar - Mabpharm

Alternative Names: CMAB 816

Latest Information Update: 28 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinomab
  • Developer Mabpharm
  • Class Anti-inflammatories; Antianaemics; Antigouts; Antihyperglycaemics; Antineoplastics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Heart failure therapies; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cryopyrin-associated periodic syndromes; Juvenile rheumatoid arthritis

Most Recent Events

  • 28 Sep 2022 No recent reports of development identified for preclinical development in Cryopyrin associated Periodic Syndromes in China (SC, Injection)
  • 28 Sep 2022 No recent reports of development identified for preclinical development in Juvenile-rheumatoid-arthritis in China (SC, Injection)
  • 29 Aug 2018 Preclinical trials in Cryopyrin associated Periodic Syndromes in China (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top